The abstract is read at the publisher; the summary is JClub's.
Tenofovir-sparing ART and PrEP for HIV may increase the risk of new hepatitis B virus infection or reactivation, depending on baseline HBV serology.
- Why it matters: As these tenofovir-sparing regimens are used more often, clinicians need to address HBV-related risks that can be preventable with proper screening and follow-up.
- What they did: The authors synthesize evidence across clinical scenarios and propose a practical workflow using HBV screening, vaccination, and post-switch monitoring to reduce risk during regimen transitions.
- The result: Incorporating HBV prevention and reactivation risk into switching decisions can mitigate potential harm, while the paper identifies knowledge gaps and future research priorities.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.